Postchemotherapy connective tissue diseasesmore than just rheumatism?
Malignancies occurring in association with connective tissue diseases such as rheumatoid arthritis (RA), Sj6gren's syndrome and systemic lupus erythematosus (SLE) have been described frequently enough to suggest a reasonable clinical association'. Indeed, large scale epidemiological studies have supported this association in rheumatoid arthritis'. The development of lymphomas, particularly B cell lymphomas, after long periods of active inflammatory autoimmune diseases such as RA lend support to the idea that these lymphomas are a manifestation of rheumatoid disease that is related to disease duration rather than to therapy of the underlying condition with drugs such as azathioprine'. It is fair to say however that this remains a controversial area.
Vasculitis has also been associated with malignancies and Hughes et al.4 first noted an association between hairy cell leukaemia, a malignancy of B cell origin, and polyarteritis nodosa. Since then there have been at least 21 further case reports and this association is considered to be a paraneoplastic syndrome5,6. Most other reports of vasculitis in association with malignancy have predominantly described cutaneous vasculitic rashes, including Henoch-Sch6nlein purpura'. In all these reports, the vasculitis has mostly preceded or coincided with the development of the malignancy though on rare occasions, the vasculitis developed some time after the malignancy was diagnosed.
In 1993, Loprinzi et al.8 described a syndrome of widespread joint pains and stiffness occurring after intensive chemotherapy for breast cancer -a report which stimulated a brisk correspondence. They coined the term postchemotherapy rheumatism. All the cases described were carefully evaluated for an underlying connective tissue disease with negative results. On the whole, symptoms either resolved spontaneously or required the addition of low doses of prednisolone in a small number of patients. Non-steroidal antiinflammatory agents were consistently ineffective. All the patients in the original report received combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil. A further case report' brought the number of patients with post-chemotherapy rheumatism to 24 and suggested that cyclophosphamide was most likely to have been responsible for the polyarthral-gias. Raderer suggested that the syndrome was a relatively benign self-limiting condition that did not require extensive evaluation either for skeletal metastases or for an underlying inflammatory connective tissue disease9.
A recent report described the development of SLE following chemotherapy for a malignant thymoma 10.
Certainly, there have been many case reports of autoimmune diseases such as lupus developing after excision of a benign hyperplastic thymus or malignant thymoma 11. What makes this case interesting however is that the malignant thymoma was not excised because of the poor general health of the patient who opted for a relatively conservative chemotherapy regimen with radiotherapy. SLE developed four years later and raises the question of whether the thymoma or the chemotherapy/radiotherapy was related to the development of the SLE.
We have recently seen five patients who were well until they developed either leukemia or lymphoma 12.
Following intensive combination chemotherapy, these patients all developed well defined autoimmune connective tissue diseases such as SLE or Churg-Strauss syndrome within 1-24 months of the chemotherapy and/or radiotherapy. A sixth patient developed severe Raynaud's phenomenon with digital ischaemia following seven cycles of S-Fluorouracil; other cytotoxics such as vinblastine, bleomycin and cisplatin have previously been associated with Raynauds. These patients extend the original descriptions of 'postchemotherapy rheumatism' and suggest a unique phenomenon of the development of a connective tissue disease shortly after intensive chemotherapy.
There are many possible reasons for the development of autoimmune disease following chemotherapy, not least of which is the remote possibility that the lymphoma was a disease manifestation that preceded the appearance of the connective tissue disease. The coincidental appearance of the two conditions also cannot be excluded. There are however more cogent possible explanations. In recent years there has been a change in chemotherapy regimens for malignancies with ever more toxic combinations in the search for effective remission inducing or palliative regimens. One possibility is the suggestion that gonadal ablation by chemotherapy can result in thymic hyperplasia, linking chemotherapy and the thymus 13. Taken together, the description of 24 patients with postchemotherapy rheumatism and the development of defined connective tissue diseases following chemotherapy for lymphoma or leukemia in five patients suggests that combination chemotherapy may be capable of disturbing the immune system profoundly enough to alter the normal balance of self-tolerance, possibly by altering thymic function leading to autoimmunity.
